HC Wainwright Analysts Lift Earnings Estimates for RLAY

Key Points

• HC Wainwright has raised its Q3 2025 earnings estimate for Relay Therapeutics (NASDAQ: RLAY) from ($0.48) to ($0.38), maintaining a "Buy" rating with a price target of $14.00.
• The recent earnings report revealed Relay Therapeutics reported ($0.41) EPS, outperforming estimates of ($0.49), with actual revenue of $0.70 million.
• Insider trading activity included CEO Sanjiv Patel selling 61,379 shares of the company, leading to a 7.42% decrease in their ownership.

Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - Research analysts at HC Wainwright lifted their Q3 2025 earnings per share estimates for shares of Relay Therapeutics in a note issued to investors on Tuesday, August 26th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.38) for the quarter, up from their prior estimate of ($0.48). HC Wainwright currently has a "Buy" rating and a $14.00 target price on the stock. The consensus estimate for Relay Therapeutics' current full-year earnings is ($2.55) per share. HC Wainwright also issued estimates for Relay Therapeutics' Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.62) EPS, Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.41) EPS and Q4 2026 earnings at ($0.42) EPS.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.08. The business had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.07 million.

Several other equities analysts have also issued reports on RLAY. Raymond James Financial reduced their price target on Relay Therapeutics from $29.00 to $19.00 and set a "strong-buy" rating on the stock in a research report on Friday, August 8th. Guggenheim decreased their target price on Relay Therapeutics from $30.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Relay Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $17.08.

Relay Therapeutics Stock Down 2.7%

Shares of NASDAQ RLAY traded down $0.10 during trading hours on Thursday, reaching $3.59. 1,094,896 shares of the stock traded hands, compared to its average volume of 1,456,063. The company has a market capitalization of $618.96 million, a P/E ratio of -1.84 and a beta of 1.60. Relay Therapeutics has a 52-week low of $1.77 and a 52-week high of $10.72. The company's 50-day simple moving average is $3.53 and its two-hundred day simple moving average is $3.25.

Hedge Funds Weigh In On Relay Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Murchinson Ltd. purchased a new position in shares of Relay Therapeutics in the 1st quarter worth $26,000. DRW Securities LLC purchased a new position in shares of Relay Therapeutics in the 1st quarter worth $28,000. AssuredPartners Investment Advisors LLC purchased a new position in shares of Relay Therapeutics in the 1st quarter worth $29,000. FNY Investment Advisers LLC grew its stake in shares of Relay Therapeutics by 100.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company's stock worth $34,000 after buying an additional 5,000 shares in the last quarter. Finally, Quinn Opportunity Partners LLC purchased a new position in shares of Relay Therapeutics in the 2nd quarter worth $35,000. 96.98% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Sanjiv Patel sold 61,379 shares of Relay Therapeutics stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $3.57, for a total transaction of $219,123.03. Following the transaction, the chief executive officer owned 765,288 shares in the company, valued at approximately $2,732,078.16. The trade was a 7.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brian Adams sold 18,276 shares of Relay Therapeutics stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $3.68, for a total transaction of $67,255.68. Following the completion of the sale, the insider owned 371,472 shares in the company, valued at approximately $1,367,016.96. This represents a 4.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 149,226 shares of company stock worth $542,926. Company insiders own 4.87% of the company's stock.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.